Please use this identifier to cite or link to this item:
https://doi.org/10.1111/all.12848
DC Field | Value | |
---|---|---|
dc.title | Prebiotic-supplemented partially hydrolysed cow's milk formula for the prevention of eczema in high-risk infants: A randomized controlled trial | |
dc.contributor.author | Boyle, R.J | |
dc.contributor.author | Tang, M.L.-K | |
dc.contributor.author | Chiang, W.C | |
dc.date.accessioned | 2020-10-23T07:55:55Z | |
dc.date.available | 2020-10-23T07:55:55Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Boyle, R.J, Tang, M.L.-K, Chiang, W.C (2016). Prebiotic-supplemented partially hydrolysed cow's milk formula for the prevention of eczema in high-risk infants: A randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology 71 (5) : 701-710. ScholarBank@NUS Repository. https://doi.org/10.1111/all.12848 | |
dc.identifier.issn | 0105-4538 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/179580 | |
dc.description.abstract | Background Prevention guidelines for infants at high risk of allergic disease recommend hydrolysed formula if formula is introduced before 6 months, but evidence is mixed. Adding specific oligosaccharides may improve outcomes. Objective To evaluate whether partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHF-OS) can prevent eczema in high-risk infants [ISRCTN65195597]. Methods We conducted a parallel-group, multicentre, randomized double-blind controlled trial of pHF-OS vs standard cow's milk formula. Infants with a family history of allergic disease were randomized (stratified by centre/maternal allergy) to active (n = 432) or control (n = 431) formula until 6 months of age if formula was introduced before 18 weeks. Primary outcome was cumulative incidence of eczema by 12 months in infants randomized at 0-4 weeks (375 pHF-OS, 383 control). Secondary outcomes were cumulative incidence of eczema by 12 or 18 months in all infants randomized, immune markers at 6 months and adverse events. Results Eczema occurred by 12 months in 84/293 (28.7%) infants allocated to pHF-OS at 0-4 weeks of age, vs 93/324 (28.7%) control (OR 0.98 95% CI 0.68, 1.40; P = 0.90), and 107/347 (30.8%) pHF-OS vs 112/370 (30.3%) control in all infants randomized (OR 0.99 95% CI 0.71, 1.37; P = 0.94). pHF-OS did not change most immune markers including total/specific IgE; however, pHF-OS reduced cow's milk-specific IgG1 (P < 0.0001) and increased regulatory T-cell and plasmacytoid dendritic cell percentages. There was no group difference in adverse events. Conclusion pHF-OS does not prevent eczema in the first year in high-risk infants. The immunological changes found require confirmation in a separate cohort. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | |
dc.publisher | Blackwell Publishing Ltd | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | gamma interferon | |
dc.subject | immunoglobulin E | |
dc.subject | immunoglobulin G1 | |
dc.subject | immunoglobulin G4 | |
dc.subject | interleukin 10 | |
dc.subject | interleukin 12 | |
dc.subject | interleukin 13 | |
dc.subject | interleukin 4 | |
dc.subject | interleukin 6 | |
dc.subject | oligosaccharide | |
dc.subject | polyunsaturated fatty acid | |
dc.subject | prebiotic agent | |
dc.subject | transforming growth factor beta | |
dc.subject | tumor necrosis factor alpha | |
dc.subject | allergen | |
dc.subject | biological marker | |
dc.subject | cytokine | |
dc.subject | immunoglobulin E | |
dc.subject | immunoglobulin G | |
dc.subject | prebiotic agent | |
dc.subject | Article | |
dc.subject | artificial milk | |
dc.subject | controlled study | |
dc.subject | cytokine response | |
dc.subject | double blind procedure | |
dc.subject | eczema | |
dc.subject | female | |
dc.subject | high risk infant | |
dc.subject | human | |
dc.subject | immunoglobulin blood level | |
dc.subject | infant | |
dc.subject | male | |
dc.subject | multicenter study | |
dc.subject | peripheral blood mononuclear cell | |
dc.subject | plasmacytoid dendritic cell | |
dc.subject | priority journal | |
dc.subject | randomized controlled trial | |
dc.subject | regulatory T lymphocyte | |
dc.subject | adult | |
dc.subject | animal | |
dc.subject | bovine | |
dc.subject | clinical trial | |
dc.subject | dietary supplement | |
dc.subject | eczema | |
dc.subject | immunology | |
dc.subject | incidence | |
dc.subject | Kaplan Meier method | |
dc.subject | milk | |
dc.subject | milk allergy | |
dc.subject | newborn | |
dc.subject | risk factor | |
dc.subject | Adult | |
dc.subject | Allergens | |
dc.subject | Animals | |
dc.subject | Biomarkers | |
dc.subject | Cattle | |
dc.subject | Cytokines | |
dc.subject | Dietary Supplements | |
dc.subject | Eczema | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Immunoglobulin E | |
dc.subject | Immunoglobulin G | |
dc.subject | Incidence | |
dc.subject | Infant | |
dc.subject | Infant Formula | |
dc.subject | Infant, Newborn | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Male | |
dc.subject | Milk | |
dc.subject | Milk Hypersensitivity | |
dc.subject | Prebiotics | |
dc.subject | Risk Factors | |
dc.type | Article | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1111/all.12848 | |
dc.description.sourcetitle | Allergy: European Journal of Allergy and Clinical Immunology | |
dc.description.volume | 71 | |
dc.description.issue | 5 | |
dc.description.page | 701-710 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1111_all_12848.pdf | 375.92 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License